Meropenem for Treatment of Hospital Acquired Pneumonia: A Clinical Trial
- VernacularTitle:美罗培南治疗医院获得性肺炎的临床观察
- Author:
Depeng JIANG
;
Jing XIANG
;
Jianqiong XIONG
- Publication Type:Journal Article
- Keywords:
Meropenem;
Hospital acquired pneumonia;
Treatment
- From:
Chinese Journal of Nosocomiology
2006;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of meropenem as first choice for hospital acquired pneumonia(HAP) treatment in intensive care units(ICU) in Southwest Hospital. METHODS The usage of meropenem for the patients with HAP in ICU was studied by a prospective,open,and non-comparative trial.Prior to the clinical trial,the preliminary experiment on etiologic investigation was done through bronchoalveolar lavage and blood cultures.In the trial,all patients were treated intravenously with meropenem at a dose of 1g every 8 hours and(3 to 7 days) were established as a treatment duration period. RESULTS After the meropenem therapy,35 patients(66%) showed either cure or improvement.Mortality was 11% at the end of therapy.Clinical complications were observed in 11 patients(21%),with none of them definitely related to the study drug. CONCLUSIONS Meropenem is effective and well-tolerated as monotherapy for most HAP patients in our ICU.The low mortality rate in this study might have been attributed to the first choice use of this drug.
